| Name | Hays Pharmacy Inc |
|---|---|
| Organization Name | Hays Pharmacy Inc |
| Location | 706 W Main, Alma, Nebraska 68920 |
| Type | Community/Retail Pharmacy |
| Phone | (308) 928-2022 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers.
Researchers at the University of Oxford, in collaboration with colleagues from Hannover Medical School and Martin-Luther-University Halle-Wittenberg, have discovered the specific gene mutations that are required for the development of leukemia in children with Down's syndrome.
The postal addresses of 22,500 children who had died of cancer in Britain between 1955 and 1980 were linked to emissions hotspots for specific chemicals.
› Verified 5 days ago
| NPI Number | 1659474765 |
| Organization Name | HAYS PHARMACY INC. |
| Type | Community/Retail Pharmacy |
| Address | 706 W Main St, Alma, NE 68920 |
| Phone Number | 308-928-2022 |
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers.
Researchers at the University of Oxford, in collaboration with colleagues from Hannover Medical School and Martin-Luther-University Halle-Wittenberg, have discovered the specific gene mutations that are required for the development of leukemia in children with Down's syndrome.
The postal addresses of 22,500 children who had died of cancer in Britain between 1955 and 1980 were linked to emissions hotspots for specific chemicals.
› Verified 5 days ago
News Archive
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers.
Researchers at the University of Oxford, in collaboration with colleagues from Hannover Medical School and Martin-Luther-University Halle-Wittenberg, have discovered the specific gene mutations that are required for the development of leukemia in children with Down's syndrome.
The postal addresses of 22,500 children who had died of cancer in Britain between 1955 and 1980 were linked to emissions hotspots for specific chemicals.
› Verified 5 days ago
Hays Pharmacy Inc Type: Community/Retail Pharmacy Location: 706 W Main, Alma, Nebraska 68920 Phone: (308) 928-2022 | |
Wecare Homecare Type: DME Supplier - Oxygen Equipment & Supplies Location: 101 North John, Alma, Nebraska 68920 Phone: (308) 928-9999 |